Destiny Pharma, a biotech company dedicated to the development of novel anti-infectives, has been jointly awarded a grant to fund a research collaboration with the Sheffield Centre for Antimicrobial Resistance and Biofilms at University of Sheffield.
Funded by the National Biofilms Innovation Centre (NBIC), the collaboration aims to establish the potential of Destiny Pharma’s proprietary XF drug compounds, DPD-207 and XF-73, as novel treatments for drug-resistant, bacterial and fungal infections.
The NBIC aims to form a network of research and innovation capacity collaborations with industry in the study of biofilms – bacteria which attaches to a surface and is very difficult to treat with conventional antibiotics, contributing to the increasing problem of antibiotic resistance. Destiny Pharma’s XF drugs have already demonstrated effectiveness in killing bacteria located in biofilms in early clinical studies.
Drug resistant bacteria and fungi create a significant threat across a range of ophthalmic infections and can result in vision impairment and blindness. Many chronic eye infections are caused by microbes aggregating to form a biofilm.
Neil Clark, Chief Executive Officer of Destiny Pharma, said: “Biofilms represent a significant barrier to antimicrobial treatment and this collaboration may help us identify additional clinical candidates for ocular indications in a billion-dollar market that are safe, effective and with a significantly reduced level of antimicrobial resistance.
“The project in part will further explore the potential of our lead drug, XF-73, which is also currently in Phase IIb clinical development for the prevention of post-surgical infections.”